glp-1 receptor agonist after bariatric surgery weight regain Two Years Stopping GLP-1s, Most Patients Sustain at Least Some Loss Interest in Treatment with GLP-1

Fu J, Nchambi KM, Wu H, Luo X, An X, Liu D

The question remains: are we witnessing the peak of obesity-driven M&A, or is this just the beginning of a decade-long race for dominance

This is because menopause brings hormonal changes like lower estrogen levels, which lead to a range of effects that include weight gain for many women

The medication has demonstrated significant weight loss in clinical trials, with participants losing an average of 12-15% of their body weight over 68 weeks in the STEP clinical trial programme

Dipeptidyl peptidase-4 inhibitors and the risk of acute pancreatitis in patients with type 2 diabetes in Taiwan: a population-based cohort study

Researchers matched those taking GLP-1 medications to people with the same type and stage of cancer and factors such as obesity or smoking, per the outlet